Recognition and Practice of Hypopituitarism After Traumatic Brain Injury and Subarachnoid Hemorrhage in Japan: A Survey.

Awareness Endocrinologists Hypopituitarism Neurosurgeons Practices Subarachnoid hemorrhage Traumatic brain injury

Journal

Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818

Informations de publication

Date de publication:
24 Oct 2023
Historique:
received: 16 05 2023
accepted: 25 09 2023
medline: 24 10 2023
pubmed: 24 10 2023
entrez: 24 10 2023
Statut: aheadofprint

Résumé

Individuals with traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH) are at a high risk of hypopituitarism, and should benefit from early diagnosis and management. However, data on awareness, attitudes, and practices of physicians treating hypopituitarism post-TBI/SAH are limited. The objectives of this study were to gain an understanding of the awareness of Japanese neurosurgeons and endocrinologists towards hypopituitarism post-TBI/SAH and the need for pituitary function assessments in these patients; and to assess the practices and perspectives of these specialists on screening patients with this condition. An observational, cross-sectional study was performed that included a Web-based survey of practicing neurosurgeons managing ≥ 1 new patients with TBI/SAH per year or endocrinologists with ≥ 1 new patients per year with a history of TBI/SAH. Of the 316 respondents (201 neurosurgeons [male, 95.5%]; 115 endocrinologists [male, 77.4%]), 75.6% of neurosurgeons and 81.7% of endocrinologists were aware of the probable occurrence of hypopituitarism post-TBI/SAH, and 79% neurosurgeons and 93.8% endocrinologists considered pituitary function impairment after TBI/SAH to be either very important or important. Hypopituitarism after TBI/SAH was recognized as an important concern by both neurosurgeons (79%) and endocrinologists (93.8%). Although many respondents agreed that such patients remain undiagnosed and untreated, pituitary function assessment post-TBI/SAH has only been performed to a limited extent. The awareness that post-TBI/SAH hypopituitarism is often transient and can progress over several weeks or months was lower in neurosurgeons (46.8%) than in endocrinologists (66.1%). The level of awareness of hypopituitarism post-TBI/SAH was lower among Japanese neurosurgeons than among endocrinologists. Educational programs and detailed guidance for the diagnosis and treatment of hypopituitarism post-TBI/SAH are warranted.

Identifiants

pubmed: 37874463
doi: 10.1007/s40120-023-00553-x
pii: 10.1007/s40120-023-00553-x
doi:

Types de publication

Journal Article

Langues

eng

Informations de copyright

© 2023. The Author(s).

Références

GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:56–87. https://doi.org/10.1016/S1474-4422(18)30415-0 .
doi: 10.1016/S1474-4422(18)30415-0
Toida C, Muguruma T, Gakumazawa M, et al. Age- and severity-related in-hospital mortality trends and risks of severe traumatic brain injury in Japan: a nationwide 10-year retrospective study. J Clin Med. 2021;10:1072. https://doi.org/10.3390/jcm10051072 .
doi: 10.3390/jcm10051072 pubmed: 33806639 pmcid: 7961410
Centers for Disease Control and Prevention; National Center for Injury Prevention and Control; Division of Unintentional Injury Prevention. Report to congress: the management of traumatic brain injury in children. 2018, Atlanta. https://www.cdc.gov/traumaticbraininjury/pdf/reportstocongress/managementoftbiinchildren/TBI-ReporttoCongress-508.pdf . Accessed 21 Nov 2022.
[No Authors Listed]. Consensus conference. Rehabilitation of persons with traumatic brain injury. NIH consensus development panel on rehabilitation of persons with traumatic brain injury. JAMA. 1999;282:974–83.
Krishnamurthi RV, Ikeda T, Feigin VL. Global, regional and country-specific burden of ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage: a systematic analysis of the global burden of disease study 2017. Neuroepidemiology. 2020;54:171–9. https://doi.org/10.1159/000506396 .
doi: 10.1159/000506396 pubmed: 32079017
Ikawa F, Morita A, Nakayama T, et al. A register-based SAH study in Japan: high incidence rate and recent decline trend based on lifestyle. J Neurosurg. 2020;134:983–91. https://doi.org/10.3171/2020.1.JNS192848 .
doi: 10.3171/2020.1.JNS192848 pubmed: 32217794
Kgosidialwa O, Hakami O, Muhammad Zia-Ul-Hussnain H, et al. Growth hormone deficiency following traumatic brain injury. Int J Mol Sci. 2019;20:3323. https://doi.org/10.3390/ijms20133323 .
doi: 10.3390/ijms20133323 pubmed: 31284550 pmcid: 6651180
Tanriverdi F, Schneider HJ, Aimaretti G, et al. Pituitary dysfunction after traumatic brain injury: a clinical and pathophysiological approach. Endocr Rev. 2015;36:305–42. https://doi.org/10.1210/er.2014-1065 .
doi: 10.1210/er.2014-1065 pubmed: 25950715
Popovic V, Aimaretti G, Casanueva FF, et al. Hypopituitarism following traumatic brain injury. Growth Horm IGF Res. 2005;15:177–84. https://doi.org/10.1016/j.ghir.2005.02.003 .
doi: 10.1016/j.ghir.2005.02.003 pubmed: 15935980
Schneider HJ, Kreitschmann-Andermahr I, Ghigo E, et al. Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA. 2007;298:1429–38. https://doi.org/10.1001/jama.298.12.1429 .
doi: 10.1001/jama.298.12.1429 pubmed: 17895459
Higham CE, Johannsson G, Shalet SM. Hypopituitarism. Lancet. 2016;388:2403–15. https://doi.org/10.1016/S0140-6736(16)30053-8 .
doi: 10.1016/S0140-6736(16)30053-8 pubmed: 27041067
Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, et al. Hypopituitarism. Lancet. 2007;369:1461–70. https://doi.org/10.1016/S0140-6736(07)60673-4 .
doi: 10.1016/S0140-6736(07)60673-4 pubmed: 17467517
Karamouzis I, Pagano L, Prodam F, et al. Clinical and diagnostic approach to patients with hypopituitarism due to traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), and ischemic stroke (IS). Endocrine. 2016;52:441–50. https://doi.org/10.1007/s12020-015-0796-2 .
doi: 10.1007/s12020-015-0796-2 pubmed: 26573924
Yuen KCJ, Masel B, Jaffee MS, et al. A consensus on optimization of care in patients with growth hormone deficiency and mild traumatic brain injury. Growth Horm IGF Res. 2022;66:101495. https://doi.org/10.1016/j.ghir.2022.101495 .
doi: 10.1016/j.ghir.2022.101495 pubmed: 35933894
Emelifeonwu JA, Wiggins AN, Andrews PJD. A national survey of clinical practice of surveillance for post-traumatic brain injury hypopituitarism in the United Kingdom and Ireland. Br J Neurosurg. 2020;34:20–3. https://doi.org/10.1080/02688697.2019.1699902 .
doi: 10.1080/02688697.2019.1699902 pubmed: 31858834
World Medical Association. WMA Declaration of Helsinki–ethical principles for medical research involving human subjects. 2022. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ . Accessed 26 Aug 2022.
International Council for Harmonisation. Efficacy guidelines. 2022. https://www.ich.org/page/efficacy-guidelines . Accessed 26 Aug 2022.
Nishioka H, Shimatsu A. Adult growth hormone deficiency: a practical approach to diagnosis and treatment for neurosurgeons. Jpn J Neurosurg. 2022;31:313–23. https://doi.org/10.7887/jcns.31.313 .
doi: 10.7887/jcns.31.313
Pharmaceuticals and Medical Devices Agency (PMDA). Sogroya subcutaneous injection interview form. 2022. https://www.info.pmda.go.jp/go/interview/1/620023_2412403G1020_1_004_1F.pdf . Accessed 21 Nov 2022.
Tan CL, Alavi SA, Baldeweg SE, et al. The screening and management of pituitary dysfunction following traumatic brain injury in adults: British Neurotrauma Group guidance. J Neurol Neurosurg Psychiatry. 2017;88:971–81. https://doi.org/10.1136/jnnp-2016-315500 .
doi: 10.1136/jnnp-2016-315500 pubmed: 28860331
Capizzi A, Woo J, Verduzco-Gutierrez M. Traumatic brain injury: an overview of epidemiology, pathophysiology, and medical management. Med Clin North Am. 2020;104:213–38. https://doi.org/10.1016/j.mcna.2019.11.001 .
doi: 10.1016/j.mcna.2019.11.001 pubmed: 32035565

Auteurs

Shigeyuki Tahara (S)

Department of Neurological Surgery, Nippon Medical School, Bunkyo-Ku, Tokyo, 113-8603, Japan.

Fumio Otsuka (F)

Department of General Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School, Kita-Ku, Okayama, 700-8558, Japan.

Takaaki Endo (T)

Medical Affairs Department, Novo Nordisk Pharma Ltd., Meiji Yasuda Seimei Bldg. 2-1-1 Marunouchi, Chiyoda-Ku, Tokyo, 100-0005, Japan. tend@novonordisk.com.

Classifications MeSH